Investor Relations

Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), utilizes a unique proprietary peptide excipient technology combined with highly purified botulinum toxin type A to produce a novel, longacting neuromodulator set to enter a $4.5 billion global market. In aesthetics, Revance successfully completed its Phase 3 program for DAXI in glabellar (frown) lines and is currently pursuing U.S. regulatory approval in 2020, while also running two separate Phase 2 studies in forehead lines and lateral canthal lines (crow’s feet). In therapeutics, DAXI is being studied in three indications, including a Phase 3 trial in cervical dystonia, a Phase 2 trial in adult upper limb spasticity, and a Phase 2 trial in plantar fasciitis, with plans to also study migraine. Beyond DAXI, Revance also has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.

“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc. BOTOX® is a registered trademark of Allergan, Inc.


Copyright West LLC. Minimum 15 minutes delayed.


Jeanie D. Herbert
Sr. Director, Investor Relations

Gilmartin Group
Laurence Watts
(619) 916-7620

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)

Shareholder Correspondence should
be mailed to:
P.O. Box 505000
Louisville, KY  40233
Shareholder Overnight
correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202


Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools